Bogers W M, Gorter A, Stuurman M E, Van Es L A, Daha M R
Department of Nephrology, University Hospital, Leiden, The Netherlands.
Immunology. 1989 Jun;67(2):274-80.
In the present study the clearance kinetics and tissue distribution of human polyclonal heat-aggregated serum IgA (AIgA) of different sizes in rats was studied after intravenous administration of 125I-AIgA. The 125I-AIgA of different sizes disappeared from the circulation in a biphasic manner with an initial rapid half-life (T1/2) and a second slower T1/2. The first T1/2 was related to the size of the 125I-AIgA: high molecular weight (MW) 125I-AIgA was cleared much faster than 125I-AIgA with a low MW. Relatively more degradation products were observed in blood when high MW 125I-AIgA were injected as compared to low MW 125I-AIgA. The AIgA were mainly taken up by the liver. Eight minutes after injection of high MW 125I-AIgA, 90% of the injected dose was found in the liver, whereas less than 2% was detected in the spleen. Very little activity was detectable in other organs, such as lungs, heart and kidneys. In the present study 1-3% of the injected 125I-AIgA were found in the bile. Analysis of this material revealed that low MW 125I-AIgA were transported more efficiently to the bile than high MW 125I-AIgA. To obtain more insight into the receptors involved in the clearance of 125I-AIgA, rats were pretreated with ovalbumin or asialofetuin. The clearance of 125I-AIgA of different sizes was inhibited when rats were pretreated with asialofetuin. Pretreatment with ovalbumin had no effect on the clearance rates of 125I-AIgA. These results suggest a role for carbohydrate receptors, which recognize glycoprotein-containing galactose terminal residues on Kupffer cells, in the clearance of 125I-AIgA.
在本研究中,静脉注射125I标记的人多克隆热聚集血清IgA(AIgA)后,研究了不同大小的AIgA在大鼠体内的清除动力学和组织分布。不同大小的125I-AIgA以双相方式从循环中消失,具有初始快速半衰期(T1/2)和第二个较慢的T1/2。第一个T1/2与125I-AIgA的大小有关:高分子量(MW)的125I-AIgA比低MW的125I-AIgA清除得快得多。与低MW的125I-AIgA相比,注射高MW的125I-AIgA时,血液中观察到相对更多的降解产物。AIgA主要被肝脏摄取。注射高MW的125I-AIgA八分钟后,90%的注射剂量在肝脏中被发现,而在脾脏中检测到的不到2%。在其他器官,如肺、心脏和肾脏中,几乎检测不到活性。在本研究中,1%-3%的注射125I-AIgA在胆汁中被发现。对该物质的分析表明,低MW的125I-AIgA比高MW的125I-AIgA更有效地转运到胆汁中。为了更深入了解参与125I-AIgA清除的受体,用卵清蛋白或去唾液酸胎球蛋白对大鼠进行预处理。用去唾液酸胎球蛋白预处理大鼠时,不同大小的125I-AIgA的清除受到抑制。用卵清蛋白预处理对125I-AIgA的清除率没有影响。这些结果表明,识别库普弗细胞上含半乳糖末端残基的糖蛋白的碳水化合物受体在125I-AIgA的清除中起作用。